Dr DeBernardo on the Role of PARP Inhibitors in Frontline Ovarian Cancer : vimarsana.com

Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.

Related Keywords

Robert Debernardo , Lauraj Fogarty , Uterine Cancer Research , Department Of Gynecologic Oncology , Peritoneal Surface Malignancy Program , Gynecologic Oncology , Endowed Chair , Cleveland Clinic , Parp Inhibitor , Ovarian Cancer , Frontline ,